ArticleBMC rheumatology2025
Rheumatoid arthritis continues to increase in low-middle SDI and low SDI quintiles based on GBD 1990-2021.
Article in BMC rheumatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
introductionAge-standardized incidence rate (ASIR), age-standardized prevalence rate (ASPR), and age-standardized disability-adjusted life years (ASDR) of rheumatoid arthritis (RA) and their trends at the global, regional, and national levels were determined using data from the Global Burden of Disease (GBD) 2021 study.
methodsThe burden of RA was investigated in relation to age, sex, and sociodemographic index (SDI), drawing upon data from the GBD 2021 study. The ASIR, ASPR, and ASDR at the global, regional, and national levels were extracted. The estimated annual percentage change (EAPC) in the ASIR, ASPR, and ASDR was calculated across all levels from 1990 to 2021, supplemented by cluster and frontier analyses.
resultsIn 2021, there were 17.92 million cases of RA globally, with the ASIR increasing from 10.42 to 11.8 cases per 100,000 individuals (EAPC of 0.49 [95% confidence interval: 0.46–0.52]) between 1990 and 2021. This substantial rise was consistently observed across all age and sex strata, Socio-demographic Index quintiles, and Global Burden of Disease regions. The most pronounced increase was in the low-middle SDI quintile in the ASIR for RA between 1990 and 2021. Among 54 GBD regions, the most significant increase was observed in Andean Latin America and Equatorial Guinea.
conclusionBy 2021, the global burden of RA was largely concentrated in the low-middle and low SDI quintiles, especially in Andean Latin America and Northern Africa, with the burden continuing to grow. These findings highlight an urgent need for targeted interventions in underserved regions, including enhanced early diagnosis capabilities and equitable access to disease-modifying therapies to mitigate rising disability burdens.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.